Microbiology FDA 483 (Eugia Pharma Specialities): Procedures to prevent microbiological contamination sterile drug product are not established and followed
During aseptic filling operations, procedure EP2-PRD-SOP-002, “Personnel Behaviour in Aseptic Area” and line specific intervention procedures were not followed